{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:17:58Z","timestamp":1790050678074,"version":"4.0.1"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ctrv.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T03:30:36Z","timestamp":1491535836000},"page":"190-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Immunologic approaches for the treatment of multiple myeloma"],"prefix":"10.1016","volume":"55","author":[{"given":"Leo","family":"Rasche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctrv.2017.03.010_b0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"33","key":"10.1016\/j.ctrv.2017.03.010_b0010","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2017.03.010_b0020","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2017.03.010_b0025","article-title":"Differentiation stage of myeloma plasma cells: biological and clinical significance","author":"Paiva","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2017.03.010_b0030","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","article-title":"Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases","volume":"91","author":"Rasche","year":"2012","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.ctrv.2017.03.010_b0035","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.4161\/21645515.2014.982993","article-title":"Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies","volume":"10","author":"Pyzer","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.ctrv.2017.03.010_b0040","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.ctrv.2017.03.010_b0045","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2017.03.010_b0050","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaci.2015.10.018","article-title":"IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration","volume":"137","author":"Kulkarni","year":"2016","journal-title":"J Aller Clin Immunol"},{"key":"10.1016\/j.ctrv.2017.03.010_b0055","doi-asserted-by":"crossref","first-page":"198539","DOI":"10.1155\/2014\/198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12307-011-0086-3","article-title":"The immune microenvironment of myeloma","volume":"4","author":"Noonan","year":"2011","journal-title":"Cancer Microenviron"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7\u2013H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ctrv.2017.03.010_b0070","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.03.010_b0075","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.ctrv.2017.03.010_b0080","doi-asserted-by":"crossref","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.ctrv.2017.03.010_b0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clml.2013.12.015","article-title":"Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma","volume":"14","author":"Kortuem","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/138945011794815329","article-title":"Interferon-alpha in the treatment of multiple myeloma","volume":"12","author":"Khoo","year":"2011","journal-title":"Curr Drug Targets"},{"issue":"26","key":"10.1016\/j.ctrv.2017.03.010_b0095","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2017.03.010_b0100","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1158\/1078-0432.CCR-14-3090","article-title":"A phase I dose-escalation study of antibody BI-505 in relapsed\/refractory multiple myeloma","volume":"21","author":"Hansson","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.ctrv.2017.03.010_b0105","article-title":"A phase I study of the anti-appa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients.","volume":"28","author":"Spencer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2017.03.010_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","article-title":"CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function","volume":"39","author":"Kumaresan","year":"2002","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2017.03.010_b0115","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2017.03.010_b0120","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2141.2011.08984.x","article-title":"Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner","volume":"157","author":"Masood","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0135","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctrv.2017.03.010_b0140","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2017.03.010_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b\u20132 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.ctrv.2017.03.010_b0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"Spec Issue","key":"10.1016\/j.ctrv.2017.03.010_b0155","first-page":"14","article-title":"Consistent benefit over time in elotuzumab studies","volume":"9","author":"Taylor","year":"2016","journal-title":"Am Health Drug Benefits"},{"issue":"16","key":"10.1016\/j.ctrv.2017.03.010_b0160","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0165","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.510.510","article-title":"Elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: 2-year follow-up","volume":"126","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2017.03.010_b0170","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2017.03.010_b0175","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1038\/bcj.2015.62","article-title":"Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211","volume":"5","author":"Usmani","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2017.03.010_b0180","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14263","article-title":"Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed\/refractory multiple myeloma","author":"Mateos","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2017.03.010_b0185","article-title":"Potential therapeutic targets in plasma cell disorders: a flow cytometry study","author":"Lisenko","year":"2015","journal-title":"Cytom B Clin Cytom"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0190","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2017.03.010_b0195","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2017.03.010_b0200","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"issue":"10027","key":"10.1016\/j.ctrv.2017.03.010_b0205","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0210","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0215","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3037.3037","article-title":"Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma","volume":"126","author":"Krejcik","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2017.03.010_b0220","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.ctrv.2017.03.010_b0225","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2017.03.010_b0230","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.13889","article-title":"Chimeric Antigen Receptor (CAR) therapy for multiple myeloma","volume":"172","author":"Atanackovic","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.ctrv.2017.03.010_b0235","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1096\/fasebj.10.12.8903511","article-title":"Human CD38, a cell-surface protein with multiple functions","volume":"10","author":"Mehta","year":"1996","journal-title":"FASEB J"},{"key":"10.1016\/j.ctrv.2017.03.010_b0240","first-page":"87","article-title":"Pharmacodynamic relationship between natural killer cells and daratumumab exposure in relapsed\/refractory multiple myeloma","volume":"101","author":"Casneuf","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.03.010_b0245","article-title":"A phase I trial of Sar650984, a Cd38 monoclonal antibody, in relapsed or refractory multiple myeloma","volume":"99","author":"Martin","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.03.010_b0250","article-title":"An open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma","volume":"100","author":"Mateos","year":"2015","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0255","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.507.507","article-title":"Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1\/2 study (GEN503)","volume":"126","author":"Plesner","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ctrv.2017.03.010_b0260","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2017.03.010_b0265","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0270","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.leu.2403647","article-title":"Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment","volume":"19","author":"Perez-Andres","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ctrv.2017.03.010_b0275","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2017.03.010_b0280","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.03.010_b0285","first-page":"175","article-title":"Expression levels of Cd38 and complement inhibitory proteins Cd55 and Cd59 predict response to daratumumab in multiple myeloma","volume":"100","author":"Nijhof","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ctrv.2017.03.010_b0290","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0295","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2141.2011.08794.x","article-title":"Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance","volume":"155","author":"Mraz","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2017.03.010_b0300","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3109\/10428194.2011.623257","article-title":"Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression","volume":"53","author":"Tembhare","year":"2012","journal-title":"Leukemia Lymph"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0305","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2012.09251.x","article-title":"A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma","volume":"159","author":"Bensinger","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.ctrv.2017.03.010_b0310","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.4042.4042","article-title":"BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity","volume":"120","author":"Heffner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.03.010_b0315","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2741\/4202","article-title":"Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma","volume":"19","author":"Berdeja","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"21","key":"10.1016\/j.ctrv.2017.03.010_b0320","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.758.758","article-title":"Indatuximab Ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma: clinical activity in Len\/Dex-refractory patients","volume":"122","author":"Kelly","year":"2013","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ctrv.2017.03.010_b0325","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.03.010_b0330","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2017.03.010_b0335","article-title":"Preclinical evaluation of Abbv-838, a first-in-class anti-Cs1 antibody-drug conjugate for the treatment of multiple myeloma","volume":"101","author":"Gish","year":"2016","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.ctrv.2017.03.010_b0340","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2014-04-560342","article-title":"Engineering more efficacious antibody therapy for myeloma","volume":"123","author":"van Rhee","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2017.03.010_b0345","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1158\/1078-0432.CCR-15-3111","article-title":"A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement","volume":"22","author":"Rasche","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0350","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3324\/haematol.2014.117945","article-title":"GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6","volume":"100","author":"Rasche","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0355","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjh.13976","article-title":"The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma","volume":"173","author":"Rotolo","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2017.03.010_b0360","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2017.03.010_b0365","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2017.03.010_b0370","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctrv.2017.03.010_b0375","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2017.03.010_b0380","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0385","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.ctrv.2017.03.010_b0390","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2017.03.010_b0395","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1182\/blood-2016-08-729467","article-title":"Myeloma CARs are rolling into the clinical arena","volume":"128","author":"Hudecek","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2017.03.010_b0400","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ctrv.2017.03.010_b0405","article-title":"Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma.","volume":"33","author":"Garfall","year":"2015","journal-title":"J Clin Oncol"},{"issue":"224","key":"10.1016\/j.ctrv.2017.03.010_b0410","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.ctrv.2017.03.010_b0415","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2017.03.010_b0420","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","article-title":"Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells","volume":"343","author":"Xu","year":"2014","journal-title":"Cancer Lett"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0425","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.LBA-1.LBA-1","article-title":"Remissions of multiple myeloma during a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor","volume":"126","author":"Ali","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2017.03.010_b0430","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2017.03.010_b0435","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ctrv.2017.03.010_b0440","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ctrv.2017.03.010_b0445","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.ctrv.2017.03.010_b0450","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0455","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.03.010_b0460","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from two phase 2 studies","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2017.03.010_b0465","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2017.03.010_b0470","first-page":"543","article-title":"Functional defects of T cells of lymphoma patients after different chemotherapy regimens activated by the bispecific antibody Afm11","volume":"100","author":"Dull","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ctrv.2017.03.010_b0475","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.ctrv.2017.03.010_b0480","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/jacs.5b01876","article-title":"An anti-B cell maturation antigen bispecific antibody for multiple myeloma","volume":"137","author":"Ramadoss","year":"2015","journal-title":"J Am Chem Soc"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0485","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2999.2999","article-title":"BI 836909, a novel bispecific T cell engager for the treatment of multiple myeloma induces highly specific and efficacious lysis of multiple myeloma cells in vitro and shows anti-tumor activity in vivo","volume":"126","author":"Hipp","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0490","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1798.1798","article-title":"Tuning T cell affinity improves efficacy and safety of anti-CD38 x anti-CD3 bispecific antibodies in monkeys - a potential therapy for multiple myeloma","volume":"126","author":"Moore","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2017.03.010_b0495","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci"},{"issue":"21","key":"10.1016\/j.ctrv.2017.03.010_b0500","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.139.139","volume":"122","author":"Lum","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0505","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.leu.2403264","article-title":"A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells","volume":"18","author":"Honemann","year":"2004","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ctrv.2017.03.010_b0510","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.ctrv.2017.03.010_b0515","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2017.03.010_b0520","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.291.291","article-title":"Preliminary results of a phase I Study of Nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies","volume":"124","author":"Lesokhin","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0525","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.505.505","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): keynote-023","volume":"126","author":"San Miguel","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0530","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.506.506","article-title":"A phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"126","author":"Badros","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.03.010_b0535","article-title":"Impact of Lenalidomide on T cell subset composition and PD-1 phenotype in patients with multiple myeloma","volume":"38","author":"Danhof","year":"2015","journal-title":"Oncol Res Treatment"},{"issue":"23","key":"10.1016\/j.ctrv.2017.03.010_b0540","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"288","key":"10.1016\/j.ctrv.2017.03.010_b0545","doi-asserted-by":"crossref","first-page":"p. 288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0550","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.ctrv.2017.03.010_b0555","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0560","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells","volume":"7","author":"Reusch","year":"2015","journal-title":"MAbs"},{"issue":"18","key":"10.1016\/j.ctrv.2017.03.010_b0565","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-15-0304","article-title":"A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed\/refractory multiple myeloma","volume":"21","author":"Benson","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ctrv.2017.03.010_b0570","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1182\/blood-2012-06-438028","article-title":"A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Benson","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0575","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2017.03.010_b0580","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/368126","article-title":"Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro","volume":"187","author":"Haslett","year":"2003","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.ctrv.2017.03.010_b0585","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ctrv.2017.03.010_b0590","doi-asserted-by":"crossref","first-page":"e1139662","DOI":"10.1080\/2162402X.2016.1139662","article-title":"Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro","volume":"5","author":"Kramer","year":"2016","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.ctrv.2017.03.010_b0595","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/imt.15.66","article-title":"Modulatory effects of bortezomib on host immune cell functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0600","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2007-03-078535","article-title":"Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma","volume":"111","author":"Shi","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2017.03.010_b0605","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ctrv.2017.03.010_b0610","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1615\/CritRevImmunol.v28.i2.20","article-title":"Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide","volume":"28","author":"Brode","year":"2008","journal-title":"Crit Rev Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2017.03.010_b0615","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2017.03.010_b0620","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1748-717X-9-185","article-title":"Immunological aspects of radiotherapy","volume":"9","author":"Scheithauer","year":"2014","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0625","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.bmt.1704073","article-title":"Autoimmune thrombocytopenic purpura after autologous stem cell transplantation","volume":"32","author":"Hequet","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"10.1016\/j.ctrv.2017.03.010_b0630","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1182\/blood-2015-10-676536","article-title":"A transplant \u201cimmunome\u201d screening platform defines a targetable epitope fingerprint of multiple myeloma","volume":"127","author":"Schieferdecker","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2017.03.010_b0635","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2017.03.010_b0640","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2017.03.010_b0645","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up","volume":"29","author":"Bjorkstrand","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2017.03.010_b0650","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.43.43","article-title":"Autologous followed by allogeneic versus tandemautologous stem cell transplant in newly diagnosed FISH-del13q myeloma","volume":"124","author":"Knop","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2017.03.010_b0655","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2017.03.010_b0660","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2017.03.010_b0665","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2017.03.010_b0670","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3109\/10428194.2015.1052808","article-title":"When to recommend allogeneic transplant in multiple myeloma","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.ctrv.2017.03.010_b0675","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17474086.2014.857270","article-title":"Allogeneic transplantation in multiple myeloma","volume":"7","author":"Gahrton","year":"2014","journal-title":"Exp Rev Hematol"},{"issue":"11","key":"10.1016\/j.ctrv.2017.03.010_b0680","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.bbmt.2016.08.024","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease and high risk cytogenetic features","volume":"22","author":"Rasche","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.ctrv.2017.03.010_b0685","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/leu.2014.145","article-title":"Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis","volume":"28","author":"Stern","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.ctrv.2017.03.010_b0690","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","article-title":"Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update","volume":"115","author":"Seggewiss","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctrv.2017.03.010_b0695","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.V98.13.3505","article-title":"Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation","volume":"98","author":"Storek","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0700","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.beha.2008.06.003","article-title":"Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation","volume":"21","author":"Williams","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"16","key":"10.1016\/j.ctrv.2017.03.010_b0705","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2017.03.010_b0710","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","article-title":"T-cell\u2013depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect","volume":"98","author":"Alyea","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2017.03.010_b0715","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.exphem.2013.08.003","article-title":"Evolving strategies with immunomodulating drugs and tandem autologous\/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients","volume":"41","author":"Michallet","year":"2013","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.ctrv.2017.03.010_b0720","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3109\/10428194.2012.656635","article-title":"Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant","volume":"53","author":"Beitinjaneh","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.ctrv.2017.03.010_b0725","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Kroger","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ctrv.2017.03.010_b0730","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/14712598.2015.1036735","article-title":"Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs","volume":"15","author":"Festuccia","year":"2015","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2017.03.010_b0735","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12758","article-title":"Outcome of allogeneic transplantation in newly diagnosed and relapsed\/refractory multiple myeloma: long-term follow-up in a single institution","author":"Franssen","year":"2016","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2017.03.010_b0740","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bmt.2015.319","article-title":"Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation","volume":"51","author":"Ahmad","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.ctrv.2017.03.010_b0745","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ctrv.2017.03.010_b0750","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217300476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217300476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T03:45:00Z","timestamp":1601869500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217300476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":150,"alternative-id":["S0305737217300476"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.03.010","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic approaches for the treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}